262 related articles for article (PubMed ID: 19754423)
1. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.
Wang B; Zhou SF
Curr Med Chem; 2009; 16(31):4066-218. PubMed ID: 19754423
[TBL] [Abstract][Full Text] [Related]
2. Insights into the structure, function, and regulation of human cytochrome P450 1A2.
Zhou SF; Chan E; Zhou ZW; Xue CC; Lai X; Duan W
Curr Drug Metab; 2009 Sep; 10(7):713-29. PubMed ID: 19702529
[TBL] [Abstract][Full Text] [Related]
3. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.
Zhou SF; Wang B; Yang LP; Liu JP
Drug Metab Rev; 2010 May; 42(2):268-354. PubMed ID: 19961320
[TBL] [Abstract][Full Text] [Related]
4. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.
Zhou SF; Yang LP; Zhou ZW; Liu YH; Chan E
AAPS J; 2009 Sep; 11(3):481-94. PubMed ID: 19590965
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human cytochrome P450 1A1-, 1A2-, and 1B1-mediated activation of procarcinogens to genotoxic metabolites by polycyclic aromatic hydrocarbons.
Shimada T; Guengerich FP
Chem Res Toxicol; 2006 Feb; 19(2):288-94. PubMed ID: 16485905
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and Mechanism of Human Cytochrome P450 Enzyme 1A2.
Guo J; Zhu X; Badawy S; Ihsan A; Liu Z; Xie C; Wang X
Curr Drug Metab; 2021; 22(1):40-49. PubMed ID: 33397254
[TBL] [Abstract][Full Text] [Related]
7. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1.
Jerabek P; Martinek V; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():25-32. PubMed ID: 23353840
[TBL] [Abstract][Full Text] [Related]
8. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.
Zhou SF; Zhou ZW; Yang LP; Cai JP
Curr Med Chem; 2009; 16(27):3480-675. PubMed ID: 19515014
[TBL] [Abstract][Full Text] [Related]
9. Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice.
Shimada T; Inoue K; Suzuki Y; Kawai T; Azuma E; Nakajima T; Shindo M; Kurose K; Sugie A; Yamagishi Y; Fujii-Kuriyama Y; Hashimoto M
Carcinogenesis; 2002 Jul; 23(7):1199-207. PubMed ID: 12117779
[TBL] [Abstract][Full Text] [Related]
10. Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors.
Shimada T; Murayama N; Okada K; Funae Y; Yamazaki H; Guengerich FP
Chem Res Toxicol; 2007 Mar; 20(3):489-96. PubMed ID: 17291012
[TBL] [Abstract][Full Text] [Related]
11. Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2.
Yang LP; Zhou ZW; Chen XW; Li CG; Sneed KB; Liang J; Zhou SF
Xenobiotica; 2012 Mar; 42(3):238-55. PubMed ID: 21970686
[TBL] [Abstract][Full Text] [Related]
12. Ortho-Methylarylamines as Time-Dependent Inhibitors of Cytochrome P450 1A1 Enzyme.
Sridhar J; Liu J; Komati R; Schroeder R; Jiang Q; Tram P; Riley K; Foroozesh M
Drug Metab Lett; 2017; 10(4):270-277. PubMed ID: 28000546
[TBL] [Abstract][Full Text] [Related]
13. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2.
Sansen S; Yano JK; Reynald RL; Schoch GA; Griffin KJ; Stout CD; Johnson EF
J Biol Chem; 2007 May; 282(19):14348-55. PubMed ID: 17311915
[TBL] [Abstract][Full Text] [Related]
14. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.
Granfors MT; Backman JT; Laitila J; Neuvonen PJ
Br J Clin Pharmacol; 2004 Mar; 57(3):349-53. PubMed ID: 14998432
[TBL] [Abstract][Full Text] [Related]
15. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.
Zhou SF; Liu JP; Lai XS
Curr Med Chem; 2009; 16(21):2661-805. PubMed ID: 19601803
[TBL] [Abstract][Full Text] [Related]
16. In vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide).
Bournique B; Lambert N; Boukaiba R; Martinet M
Br J Clin Pharmacol; 2001 Jul; 52(1):53-63. PubMed ID: 11453890
[TBL] [Abstract][Full Text] [Related]
17. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450.
Muto S; Fujita K; Yamazaki Y; Kamataki T
Mutat Res; 2001 Aug; 479(1-2):197-206. PubMed ID: 11470492
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of procarcinogen-bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin.
Chang TK; Chen J; Yang G; Yeung EY
J Pineal Res; 2010 Jan; 48(1):55-64. PubMed ID: 19919601
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human cytochrome P450 1B1, 1A1 and 1A2 by antigenotoxic compounds, purpurin and alizarin.
Takahashi E; Fujita K; Kamataki T; Arimoto-Kobayashi S; Okamoto K; Negishi T
Mutat Res; 2002 Oct; 508(1-2):147-56. PubMed ID: 12379470
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
Lu P; Schrag ML; Slaughter DE; Raab CE; Shou M; Rodrigues AD
Drug Metab Dispos; 2003 Nov; 31(11):1352-60. PubMed ID: 14570767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
